Open Access<p>Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients</p>
Author(s) -
Hengrui Liang,
Caichen Li,
Yi Zhao,
Shen Zhao,
Jun Huang,
Xiuyu Cai,
Bo Cheng,
Shan Xiong,
Jianfu Li,
Wei Wang,
Changbin Zhu,
Weiwei Li,
Jianxing He,
Wenhua Liang
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s255967
Subject(s) - concomitant , medicine , t790m , mutation , epidermal growth factor receptor , oncology , gene , cancer research , gefitinib , cancer , biology , genetics
Differences in efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have been observed between non-small cell lung cancer (NSCLC) patients with 19 exon deletion (19Del) and L858R mutation. We explored whether the total number or pattern of concomitant mutations of 19Del and L858R may explain their different sensitivities.